Nirvana Life Sciences (NIRV.X) 주식 개요는 중독 문제를 해결하기 위한 치료 제품을 연구 및 개발하는 회사입니다. 자세히 보기NIRV.X 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6강점지난 5년 동안 수입이 매년 39.4% 증가했습니다.위험 분석지난 1년 동안 주주가 크게 희석되었습니다.cash runway 경력이 1년 미만입니다.수익이 USD$1m 미만입니다(CA$0)마이너스 주주 지분+ 위험 2건 추가모든 위험 점검 보기NIRV.X Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.01해당 없음내재 할인율Est. Revenue$PastFuture-6m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.1AdvancedSet Fair ValueView all narrativesFeatured narrative•Pharmaceuticals & Biotech opportunityUnicycive Therapeutics4 months ago author updated this narrativeSTFair Value from stuart_robertsUS$21.5363.5% 저평가 내재 할인율Looking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read full narrative6.3kusers have viewed this narrative18users have liked this narrative0users have commented on this narrative130users have followed this narrativeRead narrativeNirvana Life Sciences Inc. 경쟁사Lowell FarmsSymbol: CNSX:LOWLMarket cap: CA$272.2kCaptor CapitalSymbol: CNSX:CPTRMarket cap: CA$802.0kLophos HoldingsSymbol: CNSX:MESCMarket cap: CA$858.6kSteep HillSymbol: CNSX:STPHMarket cap: CA$889.8k가격 이력 및 성과Nirvana Life Sciences 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.0152주 최고가CA$0.1452주 최저가CA$0.005베타-0.571개월 변동100.00%3개월 변동n/a1년 변동-83.33%3년 변동-97.50%5년 변동n/aIPO 이후 변동-99.83%최근 뉴스 및 업데이트Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.더 많은 업데이트 보기Recent updatesBoard Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Sep 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Sep 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jul 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jul 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jun 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • May 05Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공지 • Mar 07Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025. Location: british columbia, vancouver CanadaBoard Change • Feb 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Nov 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$314k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$314k free cash flow). Negative equity (-CA$753k). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.45m market cap, or US$1.05m). Minor Risk Shareholders have been diluted in the past year (42% increase in shares outstanding).New Risk • Oct 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$548k). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.82m market cap, or US$3.52m). Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Shareholders have been diluted in the past year (42% increase in shares outstanding).공지 • Oct 19Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023.공지 • Jun 08Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million.Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million on June 7, 2023. Nirvana Life Sciences Inc. acquired Medsmart in exchange for 5 million shares of Nirvana valued at $0.10 per share.공지 • May 11Nirvana Life Sciences Inc. announced a financing transactionNirvana Life Sciences Inc. announced a CAD 0.05 unit private placement on May 10, 2023. Each unit consisting of one common share and one half common share purchase warrant, each full warrant exercisable for an additional common share for aggregate gross proceeds of CAD 320,000. The company will now issue 6,400,000 common shares and 3,200,000 common share purchase warrants, each warrant being exercisable at CAD 0.15 per common share for a period of 24 months from date of issuance. On the same date, The company received investment in its first tranche closing.Board Change • Jan 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공지 • Nov 10Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of DirectorsNirvana Life Sciences Inc. announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors. Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful investing experience and an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests. He founded ThreeD Capital to provide unique investment opportunities in several areas, specifically early stages of small cap stock, resource and disruptive technologies. Sheldon graduated from the University of Toronto with a B.Comm degree and, later, was awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur, philanthropist and for his dedication to youth.공지 • Sep 08Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two ThirdsNirvana Life Sciences Inc. report the development of a more efficient method for producing MDMA. Nirvana Life Sciences Inc. announced the development of a novel method of producing MDMA (3,4-methylenedioxy methamphetamine) that greatly reduces manufacturing time. This 3-step synthesis, starting from the precursor safrole, takes as little as 24 hours to complete, depending upon which method of reduction of the ketone to the secondary amine is being used. This is approximately one third of the time that's required to complete current production methods using iso-safrole as an intermediate. Nirvana has filed an Application with the US Patent Office for this invention. MDMA was first synthesized in 1912, but it was not researched for its therapeutic potential until just recently. The drug is a potent central nervous system (CNS) stimulant the varies greatly in effect from other common stimulants found in the same phenethylamine family of compounds. It is currently being studied and used for the treatment of a wide range of psychiatric disorders such as Post Traumatic Stress Disorder (PTSD), depression and anxiety to name a few. MDMA assisted psychotherapy is currently in phase three clinical trials for the treatment of PTSD in the US, Canada, and Israel. This year the FDA expanded access to MDMA, allowing for its compassionate use in clinical settings by patients who have had no success with other FDA approved treatment options. MDMA effectively shuts down the brain's fight-or-flight response and creates a sense of empathy in patients, allowing them to process trauma more effectively. The drug increases the amount of serotonin in the synaptic clefts of serotonergic neurons. It also binds to various serotonin receptors and activates them in excess, while simultaneously reducing the reuptake of other neurotransmitters, which is the drugs primary mechanism of action Lead chemist and Head of Innovation for Nirvana Life Sciences Inc., Robert August, was one of the first researchers to successfully crystallize MDMA HCl Monohydrate, a novel form of MDMA with increased bioavailability and efficacy. The method of synthesis that he developed can also be seamlessly integrated into the production of MDMA HCl Monohydrate, of which Nirvana Life Sciences Inc. recently announced a patent pending for. With the growing surge in interest in the research of MDMA in the past few years, and the increasing potentials of its use in therapeutic settings, Nirvana believes that this breakthrough is a significant advance in the emerging psychedelic medicines space.공지 • Aug 09Nirvana Life Sciences Inc. Announces Executive ChangesNirvana Life Sciences Inc. announced that Connie Hang has resigned as Chief Financial Officer of the Company. She will continue serving the Company as a Contractor. Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years' experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors. Ms Storey has a keen interest in the development new approaches to manage addictions and currently serves as a director of the advocacy group Moms Stop the Harm.공지 • Jun 24Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug CompoundNirvana Life Sciences Inc. reported that it has filed a provisional patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin compound. The process, developed by Nirvana's Head of Innovation, Robert August allows for the isolation of 4- PO-Psilocin, a substituted tryptamine and psychoactive prodrug that is produced alongside psilocybin and psilocin. Its pharmacological effects are virtually identical to those produced by psilocybin since both are prodrugs. Both are metabolized in the human body to produce the psychoactive compound psilocin, which is responsible for the majority of psychoactive effects. The 4-PO-Psilocin can be purified by crystallization to an API. It can also be converted to a biologically active and water-soluble salt to yield a final compound 4-PO-Psilocin with a purity greater than 99%. The ability to convert the 4-PO-Psilocin compound into a water-soluble salt will change the current landscape of delivery systems in the psychedelic sector. The high rate of bioavailability will lower the required volume of psychedelic compound to achieve the same result. This will substantially increase the efficacy and safety in administering psychedelic compounds in clinical settings.공지 • Jun 11Nirvana Life Sciences Announces Patent FilingNirvana Life Sciences Inc. report that it has filed a new provisional patent application with the United States Patent and Trademark Office entitled Method of Psilocybin Extraction and Method of use of Psilocybin in modulating Heroin and Memory Retrieval (the "Patent Application"). The Patent Application contains new inventive claims for extraction as well as inventive methods for use of Psilocybin to affect relapse and further demonstrates the progress that the Company is making toward developing products that can have a meaningful impact on opioid addiction.공지 • Jun 04Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug StudyNirvana Life Sciences Inc. in conjunction with Integrative Therapy Discovery Labs in Italy, have released comprehensive data on a scientific study that aims in determining the effects that psilocybin has on the heroin addicted brain. The study was carried out by Dr. Massimo Nabissi, from the School of Pharmacy Section of Experimental Medicine, University of Camerino in Camerino, Italy. The preclinical study evaluated the effect of psilocybin on in-vitro rat brain cell line models and an in-vivo rat model on heroin self-administration and reinstatement of heroin seeking behavior following memory retrieval tests. Drug self-administration is regarded as a gold-standard preclinical model of addiction and substance-use disorders. The aim of the project was threefold and are as follows. To evaluate the effect of psilocybin in modulating heroin molecular pathways in vitro rat brain cell line models. To evaluate the effect of psilocybin on heroin self-administration. To evaluate the effect of psilocybin on reinstatement of heroin seeking following memory retrieval test. Gene Analysis was performed by the Clariom S Assay tool. This machine serves as a next generation transcriptome-wide gene-level expression profiling tool, which allows for the fastest, simplest, and most scalable path to generating actionable results. Based on industry-leading microarray technology, the novel rat Clariom S Assay provides extensive coverage of all known well-annotated genes, compatibility with clinical sample types, scalable formats, and flexible data analysis software. The GeneChip Rat Genome 230 2.0 Assay was used to evaluate gene expression levels and in cell lines that were treated with heroin and psilocybin and with psilocybin in combination with heroin. The immortalized rat hypothalamus cells were derived from the hypothalamus of a 4-month-old Fisher Rat. The hippocampal cells derived from the rats' hippocampi were treated daily with heroin and psilocybin, alone or in combination. After 48 hours, cell lines were collected for RNA extraction and gene array analysis. For each of the comparisons indicated, an electronic file was created that includes differentially expressed transcripts that were identified in both H19-7 and RCTH-1 cells with extended annotations. A second file was created that made comparisons evidencing only the transcript differences where the Ct value was highly different as a final analysis. For each of these data sets, only the genes whose expression was reverted by psilocybin and in the treatments consisting of heroin plus psilocybin were selected. Moreover, only the genes whose expression was psilocybin dose dependent were considered. In summary, the potential candidate genes whose expression in heroin treatment was reverted by psilocybin and evidenced in the electronic file reports were selected. The effect of heroin and psilocybin in reducing cell viability was evaluated in HT19-7 and RCHT-1 cell lines by daily administration. Cells were treated for 48 hours with either heroin or psilocybin or with a combination of heroin with psilocybin and then were analyzed. The percentage of cell viability was evaluated by a cell viability assay whose results showed a dose-dependent heroin effect in the RCHT-1 cell line with specific IC50 values. While in HT19-7 cell lines, no cytotoxic effects were observed at the concentrations used. Regarding psilocybin, similar results were obtained in cell lines with specific IC50 values and with both RCHT-1 and HT19-7 cell lines. To gain further insight, heroin was combined with psilocybin at varying doses to evaluate the optimal combination for transcriptional study. The results showed that when used together at varying dosages, the combinations were not cytotoxic in either of the two cell lines. The study goes on to show how treatment with psilocybin effected self-administered heroin use via lever presses along with the overall effect that psilocybin combined with heroin had on certain behavioral models in both male and female Wistar rat populations. A preliminary experiment aimed at testing the efficacy of psilocybin to prevent heroin relapse following cue memory reconsolidation was also conducted. Altogether, these results suggest that psilocybin decreased reinstatement of heroin seeking in female rats. As a final analysis, the gene data evidenced in the study was subjected to a comprehensive academic wide search of available current littérature and, although information regarding a correlation with psilocybin and opioid addiction was available, a transcriptome analysis for heroin and psilocybin and their co-combination has never been previously investigated. As a result, the data presented in this study can be extremely useful for determining a better understanding of dependent doses and the molecular mechanisms involved in the potential modulation of heroin (or opioids in general) addiction and dependence. In summary, the information contained within the study dealing with relapse prevention is new and groundbreaking evidence in the field of pharmaceutical addictions medicine and chemotherapy. This type of comprehensive study, which constitutes concrete scientific evidence-based data, is at the heart of Nirvana Life Sciences' business objective which is to develop and seek FDA approval for therapeutic formulations and novel pharmaceuticals.공지 • Jun 01Nirvana Life Sciences Inc. announced that it has received CAD 0.15 million in funding from ThreeD Capital Inc.Nirvana Life Sciences Inc. (CNSX:NIRV) announced a non-brokered private placement of 500,000 units at a price of CAD 0.30 per unit for gross proceeds of CAD 150,000 from returning investor ThreeD Capital Inc. on May 31, 2022. Each unit consists of one share and one warrant to purchase a share at a price of CAD 0.50 per share with an expiry date of May 29, 2025. The shares issued will be subject to a statutory four-month hold period.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공지 • Apr 06Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory BoardNirvana Life Sciences Inc. announced the appointment of Mr. Andrew Samann to the Company's Advisory Board. Andrew Samann is CEO and Principal Consultant of Orion GMP Solutions.주주 수익률NIRV.XCA PharmaceuticalsCA 시장7D0%6.2%2.3%1Y-83.3%59.0%34.5%전체 주주 수익률 보기수익률 대 산업: NIRV.X은 지난 1년 동안 59%의 수익을 기록한 Canadian Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: NIRV.X은 지난 1년 동안 34.5%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.주가 변동성Is NIRV.X's price volatile compared to industry and market?NIRV.X volatilityNIRV.X Average Weekly Movementn/aPharmaceuticals Industry Average Movement12.1%Market Average Movement10.3%10% most volatile stocks in CA Market17.8%10% least volatile stocks in CA Market4.0%안정적인 주가: NIRV.X의 주가는 지난 3개월 동안 Canadian 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine NIRV.X의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트n/an/aBruce Clarknirvanalifescience.com는 중독 문제를 해결하기 위한 치료 제품을 연구 및 개발하는 회사입니다. 이 회사는 캐나다 밴쿠버에 본사를 두고 있습니다.더 보기Nirvana Life Sciences Inc. 기초 지표 요약Nirvana Life Sciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?NIRV.X 기초 통계시가총액CA$229.23k순이익 (TTM)-CA$358.63k매출 (TTM)n/a0.0x주가매출비율(P/S)-0.6x주가수익비율(P/E)NIRV.X는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표NIRV.X 손익계산서 (TTM)매출CA$0매출원가CA$0총이익CA$0기타 비용CA$358.63k순이익-CA$358.63k최근 보고된 실적Jan 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-0.016총이익률0.00%순이익률0.00%부채/자본 비율-20.0%NIRV.X의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 07:28종가2026/04/23 00:00수익2026/01/31연간 수익2025/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nirvana Life Sciences Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Featured narrative•Pharmaceuticals & Biotech opportunityUnicycive Therapeutics4 months ago author updated this narrativeSTFair Value from stuart_robertsUS$21.5363.5% 저평가 내재 할인율Looking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read full narrative6.3kusers have viewed this narrative18users have liked this narrative0users have commented on this narrative130users have followed this narrativeRead narrative
Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Dec 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Oct 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Sep 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Sep 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jul 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jul 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jun 19Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • May 05Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공지 • Mar 07Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025Nirvana Life Sciences Inc., Annual General Meeting, Apr 30, 2025. Location: british columbia, vancouver Canada
Board Change • Feb 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Mark Marissen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Nov 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$314k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$314k free cash flow). Negative equity (-CA$753k). Revenue is less than US$1m. Market cap is less than US$10m (CA$1.45m market cap, or US$1.05m). Minor Risk Shareholders have been diluted in the past year (42% increase in shares outstanding).
New Risk • Oct 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$548k). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.82m market cap, or US$3.52m). Minor Risks Latest financial reports are more than 6 months old (reported January 2023 fiscal period end). Shareholders have been diluted in the past year (42% increase in shares outstanding).
공지 • Oct 19Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023Nirvana Life Sciences Inc., Annual General Meeting, Dec 18, 2023.
공지 • Jun 08Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million.Nirvana Life Sciences Inc. (CNSX:NIRV) has entered into a definitive agreement to acquire Medsmart Dispensary Inc. for $0.13 million on June 7, 2023. Nirvana Life Sciences Inc. acquired Medsmart in exchange for 5 million shares of Nirvana valued at $0.10 per share.
공지 • May 11Nirvana Life Sciences Inc. announced a financing transactionNirvana Life Sciences Inc. announced a CAD 0.05 unit private placement on May 10, 2023. Each unit consisting of one common share and one half common share purchase warrant, each full warrant exercisable for an additional common share for aggregate gross proceeds of CAD 320,000. The company will now issue 6,400,000 common shares and 3,200,000 common share purchase warrants, each warrant being exercisable at CAD 0.15 per common share for a period of 24 months from date of issuance. On the same date, The company received investment in its first tranche closing.
Board Change • Jan 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공지 • Nov 10Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of DirectorsNirvana Life Sciences Inc. announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors. Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful investing experience and an extensive track record of achieving significant ROI for his investors and profitability for the companies in which he invests. He founded ThreeD Capital to provide unique investment opportunities in several areas, specifically early stages of small cap stock, resource and disruptive technologies. Sheldon graduated from the University of Toronto with a B.Comm degree and, later, was awarded an honorary Doctor of Law degree from the university for his leadership as an entrepreneur, philanthropist and for his dedication to youth.
공지 • Sep 08Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two ThirdsNirvana Life Sciences Inc. report the development of a more efficient method for producing MDMA. Nirvana Life Sciences Inc. announced the development of a novel method of producing MDMA (3,4-methylenedioxy methamphetamine) that greatly reduces manufacturing time. This 3-step synthesis, starting from the precursor safrole, takes as little as 24 hours to complete, depending upon which method of reduction of the ketone to the secondary amine is being used. This is approximately one third of the time that's required to complete current production methods using iso-safrole as an intermediate. Nirvana has filed an Application with the US Patent Office for this invention. MDMA was first synthesized in 1912, but it was not researched for its therapeutic potential until just recently. The drug is a potent central nervous system (CNS) stimulant the varies greatly in effect from other common stimulants found in the same phenethylamine family of compounds. It is currently being studied and used for the treatment of a wide range of psychiatric disorders such as Post Traumatic Stress Disorder (PTSD), depression and anxiety to name a few. MDMA assisted psychotherapy is currently in phase three clinical trials for the treatment of PTSD in the US, Canada, and Israel. This year the FDA expanded access to MDMA, allowing for its compassionate use in clinical settings by patients who have had no success with other FDA approved treatment options. MDMA effectively shuts down the brain's fight-or-flight response and creates a sense of empathy in patients, allowing them to process trauma more effectively. The drug increases the amount of serotonin in the synaptic clefts of serotonergic neurons. It also binds to various serotonin receptors and activates them in excess, while simultaneously reducing the reuptake of other neurotransmitters, which is the drugs primary mechanism of action Lead chemist and Head of Innovation for Nirvana Life Sciences Inc., Robert August, was one of the first researchers to successfully crystallize MDMA HCl Monohydrate, a novel form of MDMA with increased bioavailability and efficacy. The method of synthesis that he developed can also be seamlessly integrated into the production of MDMA HCl Monohydrate, of which Nirvana Life Sciences Inc. recently announced a patent pending for. With the growing surge in interest in the research of MDMA in the past few years, and the increasing potentials of its use in therapeutic settings, Nirvana believes that this breakthrough is a significant advance in the emerging psychedelic medicines space.
공지 • Aug 09Nirvana Life Sciences Inc. Announces Executive ChangesNirvana Life Sciences Inc. announced that Connie Hang has resigned as Chief Financial Officer of the Company. She will continue serving the Company as a Contractor. Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years' experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors. Ms Storey has a keen interest in the development new approaches to manage addictions and currently serves as a director of the advocacy group Moms Stop the Harm.
공지 • Jun 24Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug CompoundNirvana Life Sciences Inc. reported that it has filed a provisional patent application for a novel process for the isolation of a psychedelic 4-PO-Psilocin compound. The process, developed by Nirvana's Head of Innovation, Robert August allows for the isolation of 4- PO-Psilocin, a substituted tryptamine and psychoactive prodrug that is produced alongside psilocybin and psilocin. Its pharmacological effects are virtually identical to those produced by psilocybin since both are prodrugs. Both are metabolized in the human body to produce the psychoactive compound psilocin, which is responsible for the majority of psychoactive effects. The 4-PO-Psilocin can be purified by crystallization to an API. It can also be converted to a biologically active and water-soluble salt to yield a final compound 4-PO-Psilocin with a purity greater than 99%. The ability to convert the 4-PO-Psilocin compound into a water-soluble salt will change the current landscape of delivery systems in the psychedelic sector. The high rate of bioavailability will lower the required volume of psychedelic compound to achieve the same result. This will substantially increase the efficacy and safety in administering psychedelic compounds in clinical settings.
공지 • Jun 11Nirvana Life Sciences Announces Patent FilingNirvana Life Sciences Inc. report that it has filed a new provisional patent application with the United States Patent and Trademark Office entitled Method of Psilocybin Extraction and Method of use of Psilocybin in modulating Heroin and Memory Retrieval (the "Patent Application"). The Patent Application contains new inventive claims for extraction as well as inventive methods for use of Psilocybin to affect relapse and further demonstrates the progress that the Company is making toward developing products that can have a meaningful impact on opioid addiction.
공지 • Jun 04Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug StudyNirvana Life Sciences Inc. in conjunction with Integrative Therapy Discovery Labs in Italy, have released comprehensive data on a scientific study that aims in determining the effects that psilocybin has on the heroin addicted brain. The study was carried out by Dr. Massimo Nabissi, from the School of Pharmacy Section of Experimental Medicine, University of Camerino in Camerino, Italy. The preclinical study evaluated the effect of psilocybin on in-vitro rat brain cell line models and an in-vivo rat model on heroin self-administration and reinstatement of heroin seeking behavior following memory retrieval tests. Drug self-administration is regarded as a gold-standard preclinical model of addiction and substance-use disorders. The aim of the project was threefold and are as follows. To evaluate the effect of psilocybin in modulating heroin molecular pathways in vitro rat brain cell line models. To evaluate the effect of psilocybin on heroin self-administration. To evaluate the effect of psilocybin on reinstatement of heroin seeking following memory retrieval test. Gene Analysis was performed by the Clariom S Assay tool. This machine serves as a next generation transcriptome-wide gene-level expression profiling tool, which allows for the fastest, simplest, and most scalable path to generating actionable results. Based on industry-leading microarray technology, the novel rat Clariom S Assay provides extensive coverage of all known well-annotated genes, compatibility with clinical sample types, scalable formats, and flexible data analysis software. The GeneChip Rat Genome 230 2.0 Assay was used to evaluate gene expression levels and in cell lines that were treated with heroin and psilocybin and with psilocybin in combination with heroin. The immortalized rat hypothalamus cells were derived from the hypothalamus of a 4-month-old Fisher Rat. The hippocampal cells derived from the rats' hippocampi were treated daily with heroin and psilocybin, alone or in combination. After 48 hours, cell lines were collected for RNA extraction and gene array analysis. For each of the comparisons indicated, an electronic file was created that includes differentially expressed transcripts that were identified in both H19-7 and RCTH-1 cells with extended annotations. A second file was created that made comparisons evidencing only the transcript differences where the Ct value was highly different as a final analysis. For each of these data sets, only the genes whose expression was reverted by psilocybin and in the treatments consisting of heroin plus psilocybin were selected. Moreover, only the genes whose expression was psilocybin dose dependent were considered. In summary, the potential candidate genes whose expression in heroin treatment was reverted by psilocybin and evidenced in the electronic file reports were selected. The effect of heroin and psilocybin in reducing cell viability was evaluated in HT19-7 and RCHT-1 cell lines by daily administration. Cells were treated for 48 hours with either heroin or psilocybin or with a combination of heroin with psilocybin and then were analyzed. The percentage of cell viability was evaluated by a cell viability assay whose results showed a dose-dependent heroin effect in the RCHT-1 cell line with specific IC50 values. While in HT19-7 cell lines, no cytotoxic effects were observed at the concentrations used. Regarding psilocybin, similar results were obtained in cell lines with specific IC50 values and with both RCHT-1 and HT19-7 cell lines. To gain further insight, heroin was combined with psilocybin at varying doses to evaluate the optimal combination for transcriptional study. The results showed that when used together at varying dosages, the combinations were not cytotoxic in either of the two cell lines. The study goes on to show how treatment with psilocybin effected self-administered heroin use via lever presses along with the overall effect that psilocybin combined with heroin had on certain behavioral models in both male and female Wistar rat populations. A preliminary experiment aimed at testing the efficacy of psilocybin to prevent heroin relapse following cue memory reconsolidation was also conducted. Altogether, these results suggest that psilocybin decreased reinstatement of heroin seeking in female rats. As a final analysis, the gene data evidenced in the study was subjected to a comprehensive academic wide search of available current littérature and, although information regarding a correlation with psilocybin and opioid addiction was available, a transcriptome analysis for heroin and psilocybin and their co-combination has never been previously investigated. As a result, the data presented in this study can be extremely useful for determining a better understanding of dependent doses and the molecular mechanisms involved in the potential modulation of heroin (or opioids in general) addiction and dependence. In summary, the information contained within the study dealing with relapse prevention is new and groundbreaking evidence in the field of pharmaceutical addictions medicine and chemotherapy. This type of comprehensive study, which constitutes concrete scientific evidence-based data, is at the heart of Nirvana Life Sciences' business objective which is to develop and seek FDA approval for therapeutic formulations and novel pharmaceuticals.
공지 • Jun 01Nirvana Life Sciences Inc. announced that it has received CAD 0.15 million in funding from ThreeD Capital Inc.Nirvana Life Sciences Inc. (CNSX:NIRV) announced a non-brokered private placement of 500,000 units at a price of CAD 0.30 per unit for gross proceeds of CAD 150,000 from returning investor ThreeD Capital Inc. on May 31, 2022. Each unit consists of one share and one warrant to purchase a share at a price of CAD 0.50 per share with an expiry date of May 29, 2025. The shares issued will be subject to a statutory four-month hold period.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Advisory Board Andrew Samann was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공지 • Apr 06Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory BoardNirvana Life Sciences Inc. announced the appointment of Mr. Andrew Samann to the Company's Advisory Board. Andrew Samann is CEO and Principal Consultant of Orion GMP Solutions.
